Dynamic Technology Lab Private Ltd Sells 10,332 Shares of DexCom, Inc. (NASDAQ:DXCM)

Dynamic Technology Lab Private Ltd decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 72.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,999 shares of the medical device company's stock after selling 10,332 shares during the period. Dynamic Technology Lab Private Ltd's holdings in DexCom were worth $311,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA raised its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom in the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DXCM. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $99.00.

Remove Ads

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last quarter. 0.30% of the stock is owned by company insiders.

DexCom Trading Up 1.0 %

Shares of DXCM stock traded up $0.66 during trading hours on Tuesday, reaching $68.05. 835,264 shares of the stock were exchanged, compared to its average volume of 4,181,063. The firm has a market capitalization of $26.68 billion, a price-to-earnings ratio of 47.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $139.24. The company's 50-day moving average price is $76.49 and its 200-day moving average price is $76.68. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.